APA (7th ed.) Citation

CL, G., HX, Z., L, D., XQ, M., K, L., W, X., . . . HM, H. (2022). Bispecific antibody simultaneously targeting PD1 and HER2 inhibits tumor growth via direct tumor cell killing in combination with PD1/PDL1 blockade and HER2 inhibition. Acta pharmacologica Sinica, 43(3), 672. https://doi.org/10.1038/s41401-021-00683-8

Chicago Style (17th ed.) Citation

CL, Gu, et al. "Bispecific Antibody Simultaneously Targeting PD1 and HER2 Inhibits Tumor Growth via Direct Tumor Cell Killing in Combination with PD1/PDL1 Blockade and HER2 Inhibition." Acta Pharmacologica Sinica 43, no. 3 (2022): 672. https://doi.org/10.1038/s41401-021-00683-8.

MLA (9th ed.) Citation

CL, Gu, et al. "Bispecific Antibody Simultaneously Targeting PD1 and HER2 Inhibits Tumor Growth via Direct Tumor Cell Killing in Combination with PD1/PDL1 Blockade and HER2 Inhibition." Acta Pharmacologica Sinica, vol. 43, no. 3, 2022, p. 672, https://doi.org/10.1038/s41401-021-00683-8.